{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T08:35:28Z","timestamp":1793349328020,"version":"4.5.0"},"reference-count":142,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T00:00:00Z","timestamp":1787356800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jtha.2026.08.017","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:59:53Z","timestamp":1787669993000},"page":"4012-4026","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The role of antifactor Xa monitoring in the dosing and administration of low-molecular-weight heparins in pregnancy: a systematic review and meta-analysis"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5287-0273","authenticated-orcid":false,"given":"Rizwana","family":"Ashraf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahab","family":"Sayfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Bowen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irving","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Shehata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4049-2017","authenticated-orcid":false,"given":"Rohan","family":"D\u2019Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2026.08.017_bib1","doi-asserted-by":"crossref","first-page":"697","DOI":"10.7326\/0003-4819-143-10-200511150-00006","article-title":"Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study","volume":"143","author":"Heit","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jtha.2026.08.017_bib2","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1538-7836.2008.02921.x","article-title":"Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study","volume":"6","author":"Pomp","year":"2008","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.08.017_bib3","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1053\/j.semperi.2019.03.004","article-title":"Venous thromboembolism as a cause of severe maternal morbidity and mortality in the United States","volume":"43","author":"Abe","year":"2019","journal-title":"Semin Perinatol"},{"key":"10.1016\/j.jtha.2026.08.017_bib4","author":"Felker"},{"key":"10.1016\/j.jtha.2026.08.017_bib5","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ejogrb.2013.03.024","article-title":"A population-based study of venous thrombosis in pregnancy in Scotland 1980-2005","volume":"169","author":"Kane","year":"2013","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.jtha.2026.08.017_bib6","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S1701-2163(16)34240-2","article-title":"Epidemiology of pregnancy-associated venous thromboembolism: a population-based study in Canada","volume":"31","author":"Liu","year":"2009","journal-title":"J Obstet Gynaecol Can"},{"key":"10.1016\/j.jtha.2026.08.017_bib8","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1161\/CIRCULATIONAHA.108.778886","article-title":"Prosthetic heart valves: selection of the optimal prosthesis and long-term management","volume":"119","author":"Pibarot","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2026.08.017_bib9","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1111\/1471-0528.13491","article-title":"Prosthetic heart valves in pregnancy, outcomes for women and their babies: a systematic review and meta-analysis","volume":"122","author":"Lawley","year":"2015","journal-title":"BJOG"},{"key":"10.1016\/j.jtha.2026.08.017_bib10","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1177\/1753495x12472642","article-title":"A systematic review on the use of new anticoagulants in pregnancy","volume":"6","author":"Tang","year":"2013","journal-title":"Obstet Med"},{"key":"10.1016\/j.jtha.2026.08.017_bib11","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1093\/eurheartj\/ehx032","article-title":"Anticoagulation for pregnant women with mechanical heart valves: a systematic review and meta-analysis","volume":"38","author":"D'Souza","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jtha.2026.08.017_bib12","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1055\/s-0036-1593418","article-title":"Optimal anticoagulation for pregnant women with mechanical heart valves","volume":"42","author":"D'Souza","year":"2016","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jtha.2026.08.017_bib13","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1182\/bloodadvances.2018024802","article-title":"American society of hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy","volume":"2","author":"Bates","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2026.08.017_bib14","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/uog.17360","article-title":"Physiological adaptation of maternal plasma volume during pregnancy: a systematic review and meta-analysis","volume":"49","author":"de Haas","year":"2017","journal-title":"Ultrasound Obstet Gynecol"},{"key":"10.1016\/j.jtha.2026.08.017_bib15","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/uog.20137","article-title":"Maternal kidney function during pregnancy: systematic review and meta-analysis","volume":"54","author":"Lopes van Balen","year":"2019","journal-title":"Ultrasound Obstet Gynecol"},{"key":"10.1016\/j.jtha.2026.08.017_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002160","article-title":"Pregnancy-associated changes in pharmacokinetics: a systematic review","volume":"13","author":"Pariente","year":"2016","journal-title":"PLoS Med"},{"key":"10.1016\/j.jtha.2026.08.017_bib17","first-page":"261","article-title":"Laboratory monitoring of low-molecular-weight heparin and fondaparinux","volume":"43","author":"Babin","year":"2017","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jtha.2026.08.017_bib18","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1046\/j.1365-2257.1999.00183.x","article-title":"Three different chromogenic methods do not give equivalent anti-Xa levels for patients on therapeutic low molecular weight heparin (dalteparin) or unfractionated heparin","volume":"21","author":"Kovacs","year":"1999","journal-title":"Clin Lab Haematol"},{"key":"10.1016\/j.jtha.2026.08.017_bib19","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1055\/s-0037-1614377","article-title":"Anti Xa monitoring during treatment with low molecular weight heparin or danaparoid: inter-assay variability","volume":"82","author":"Kitchen","year":"1999","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.08.017_bib20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1055\/s-2000-9497","article-title":"Comparative pharmacokinetics of LMWHs","volume":"26","author":"Samama","year":"2000","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jtha.2026.08.017_bib21","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1532\/LH96.05028","article-title":"How useful is the monitoring of (low molecular weight) heparin therapy by anti-Xa assay? A laboratory perspective","volume":"11","author":"Favaloro","year":"2005","journal-title":"Lab Hematol"},{"key":"10.1016\/j.jtha.2026.08.017_bib22","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1055\/s-0038-1653787","article-title":"A comparative study of three low-molecular weight heparins (LMWH) and unfractionated heparin (UH) in healthy volunteers","volume":"73","author":"Eriksson","year":"1995","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.08.017_bib23","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/jcpt.13169","article-title":"The effect of anti-Xa monitoring on the safety and efficacy of low-molecular-weight heparin anticoagulation therapy: a systematic review and meta-analysis","volume":"45","author":"Wu","year":"2020","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.jtha.2026.08.017_bib24","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1016\/j.jtha.2025.06.025","article-title":"A systematic review on anti-Xa monitoring in the therapeutic use of low-molecular-weight heparins","volume":"23","author":"Jaspers","year":"2025","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.08.017_bib25","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jtha.2026.08.017_bib28","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.08.017_bib146","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v049.i05","article-title":"Closing the gap between methodologists and end-users: R as a computational back-end","volume":"49","author":"Wallace","year":"2012","journal-title":"J Stat Softw"},{"key":"10.1016\/j.jtha.2026.08.017_bib29","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12874-025-02527-z","article-title":"Overcoming challenges in prevalence meta-analysis: the case for the Freeman-Tukey transform","volume":"25","author":"Abdulmajeed","year":"2025","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.jtha.2026.08.017_bib31","doi-asserted-by":"crossref","first-page":"427","DOI":"10.7326\/0003-4819-144-6-200603210-00010","article-title":"Evaluation of the quality of prognosis studies in systematic reviews","volume":"144","author":"Hayden","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jtha.2026.08.017_bib32","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.healun.2021.03.015","article-title":"Incidence and impact of primary graft dysfunction in adult heart transplant recipients: a systematic review and meta-analysis","volume":"40","author":"Buchan","year":"2021","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.jtha.2026.08.017_bib33","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13206","article-title":"Incidence and predictors of sudden cardiac death after heart transplantation: a systematic review and meta-analysis","volume":"32","author":"Alba","year":"2018","journal-title":"Clin Transplant"},{"key":"10.1016\/j.jtha.2026.08.017_bib34","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.h870","article-title":"Use of GRADE for assessment of evidence about prognosis: rating confidence in estimates of event rates in broad categories of patients","volume":"350","author":"Iorio","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.jtha.2026.08.017_bib35","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jclinepi.2019.12.023","article-title":"GRADE guidelines 28: use of GRADE for the assessment of evidence about prognostic factors: rating certainty in identification of groups of patients with different absolute risks","volume":"121","author":"Foroutan","year":"2020","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jtha.2026.08.017_bib36","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-081903","article-title":"Core GRADE 1: overview of the core GRADE approach","volume":"389","author":"Guyatt","year":"2025","journal-title":"BMJ"},{"key":"10.1016\/j.jtha.2026.08.017_bib37","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-083866","article-title":"Core GRADE 6: presenting the evidence in summary of findings tables","volume":"389","author":"Guyatt","year":"2025","journal-title":"BMJ"},{"key":"10.1016\/j.jtha.2026.08.017_bib38","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1177\/1753495X20924937","article-title":"Mechanical heart valves and pregnancy: issues surrounding anticoagulation. Experience from two obstetric cardiac centres","volume":"14","author":"Dos Santos","year":"2021","journal-title":"Obstet Med"},{"key":"10.1016\/j.jtha.2026.08.017_bib39","article-title":"A case series of Factor V Leiden mutation in pregnancy","volume":"6","author":"Bailly","year":"2020","journal-title":"S Afr J Obstet Gynaecol"},{"key":"10.1016\/j.jtha.2026.08.017_bib40","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1111\/jth.14452","article-title":"Effectiveness and safety of thromboprophylaxis with enoxaparin for prevention of pregnancy-associated venous thromboembolism","volume":"17","author":"Cox","year":"2019","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.08.017_bib41","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/ijgo.12764","article-title":"Safety and efficacy of adjusted-dose enoxaparin in pregnant patients with increased risk for venous thromboembolic disease","volume":"145","author":"Bailly","year":"2019","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.jtha.2026.08.017_bib42","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1080\/01443615.2017.1387521","article-title":"Anti-Xa based dose changes during low molecular weight heparin anticoagulation for mechanical prosthetic heart valves during pregnancy","volume":"38","author":"Snape","year":"2018","journal-title":"J Obstet Gynaecol"},{"key":"10.1016\/j.jtha.2026.08.017_bib43","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1177\/1753495X17741025","article-title":"Severe antithrombin deficiency in pregnancy: achieving adequate anticoagulation","volume":"12","author":"Pearson-Stuttard","year":"2019","journal-title":"Obstet"},{"key":"10.1016\/j.jtha.2026.08.017_bib44","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1111\/1471-0528.14478","article-title":"Pregnancy outcomes in women with mechanical prosthetic heart valves: a prospective descriptive population based study using the United Kingdom obstetric surveillance system (UKOSS) data collection system","volume":"124","author":"Vause","year":"2017","journal-title":"BJOG"},{"key":"10.1016\/j.jtha.2026.08.017_bib45","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s11239-016-1409-5","article-title":"Adjustment of therapeutic LMWH to achieve specific target anti-FXa activity does not affect outcomes in pregnant patients with venous thromboembolism","volume":"43","author":"McDonnell","year":"2017","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.jtha.2026.08.017_bib46","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/MBC.0000000000000573","article-title":"The value and impact of anti-Xa activity monitoring for prophylactic dose adjustment of low-molecular-weight heparin during pregnancy: a retrospective study","volume":"28","author":"Boban","year":"2017","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.jtha.2026.08.017_bib47","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s11845-013-0998-7","article-title":"Tinzaparin safety and efficacy in pregnancy","volume":"183","author":"Khalifeh","year":"2014","journal-title":"Ir J Med Sci"},{"key":"10.1016\/j.jtha.2026.08.017_bib48","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1177\/1074248414524302","article-title":"Monitoring of anti-Xa in pregnant patients with mechanical prosthetic valves receiving low-molecular-weight heparin: peak or trough levels?","volume":"19","author":"Goland","year":"2014","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.jtha.2026.08.017_bib49","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.thromres.2014.09.033","article-title":"A case series of LMWH use in pregnancy: should trough anti-Xa levels guide dosing?","volume":"134","author":"Berresheim","year":"2014","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2026.08.017_bib50","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1016\/j.thromres.2012.11.018","article-title":"Weight-adjusted dosing of tinzaparin in pregnancy","volume":"131","author":"Gibson","year":"2013","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2026.08.017_bib51","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1160\/TH13-01-0077","article-title":"How I treat heterozygous hereditary antithrombin deficiency in pregnancy","volume":"110","author":"Bramham","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.08.017_bib52","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1111\/j.1445-5994.2012.02863.x","article-title":"How do we manage venous thromboembolism in pregnancy? A retrospective review of the practice of diagnosing and managing pregnancy-related venous thromboembolism at two major hospitals in Australia and New Zealand","volume":"42","author":"Chan","year":"2012","journal-title":"Intern Med J"},{"key":"10.1016\/j.jtha.2026.08.017_bib53","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1177\/1076029610371470","article-title":"A prospective trial showing the safety of adjusted-dose enoxaparin for thromboprophylaxis of pregnant women with mechanical prosthetic heart valves","volume":"17","author":"Saeed","year":"2011","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.jtha.2026.08.017_bib54","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.ejogrb.2011.08.005","article-title":"Tinzaparin use in pregnancy: an international, retrospective study of the safety and efficacy profile","volume":"159","author":"Nelson-Piercy","year":"2011","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.jtha.2026.08.017_bib55","doi-asserted-by":"crossref","first-page":"18","DOI":"10.2298\/SARH10S1018M","article-title":"Efficacy and safety of nadroparin and unfractionated heparin for the treatment of venous thromboembolism during pregnancy and puerperium","volume":"138","author":"Miti\u0107","year":"2010","journal-title":"Srp Arh Celok Lek"},{"key":"10.1016\/j.jtha.2026.08.017_bib56","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/jp.2009.164","article-title":"Fluctuations in anti-factor Xa levels with therapeutic enoxaparin anticoagulation in pregnancy","volume":"30","author":"Friedrich","year":"2010","journal-title":"J Perinatol"},{"key":"10.1016\/j.jtha.2026.08.017_bib57","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.amjcard.2009.06.040","article-title":"Use of low molecular weight heparin in pregnant women with mechanical heart valves","volume":"104","author":"Yinon","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jtha.2026.08.017_bib58","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.3324\/haematol.2008.002840","article-title":"Use of high intensity adjusted dose low molecular weight heparin in women with mechanical heart valves during pregnancy: a single-center experience","volume":"94","author":"Quinn","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2026.08.017_bib59","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1111\/j.1471-0528.2009.02299.x","article-title":"Maternal complications and pregnancy outcome in women with mechanical prosthetic heart valves treated with enoxaparin","volume":"116","author":"McLintock","year":"2009","journal-title":"BJOG"},{"key":"10.1016\/j.jtha.2026.08.017_bib60","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.thromres.2008.12.005","article-title":"Management of pregnant women with mechanical heart valve prosthesis: thromboprophylaxis with low molecular weight heparin","volume":"124","author":"Abildgaard","year":"2009","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2026.08.017_bib61","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1080\/00016340802449118","article-title":"Treatment of deep venous thrombosis in pregnant women","volume":"87","author":"Lykke","year":"2008","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.jtha.2026.08.017_bib62","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1097\/AOG.0b013e31818638dc","article-title":"Anti-factor Xa plasma levels in pregnant women receiving low molecular weight heparin thromboprophylaxis","volume":"112","author":"Fox","year":"2008","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jtha.2026.08.017_bib63","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1097\/MBC.0b013e32830b14ef","article-title":"Efficacy and safety of once daily low molecular weight heparin (tinzaparin sodium) in high risk pregnancy","volume":"19","author":"N\u00ed Ainle","year":"2008","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.jtha.2026.08.017_bib64","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1365-2141.2007.06826.x","article-title":"The management of antenatal venous thromboembolism in the UK and Ireland: a prospective multicentre observational survey","volume":"139","author":"Voke","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2026.08.017_bib65","first-page":"679","article-title":"Low-molecular-weight heparin in pregnant women with prosthetic heart valves","volume":"15","author":"Descarries","year":"2006","journal-title":"J Heart Valve Dis"},{"key":"10.1016\/j.jtha.2026.08.017_bib66","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1177\/107602960501100206","article-title":"A protocol for the use of enoxaparin during pregnancy: results from 85 pregnancies including 13 multiple gestation pregnancies","volume":"11","author":"Huxtable","year":"2005","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.jtha.2026.08.017_bib67","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1080\/14767050500275796","article-title":"Prophylactic dosing adjustment in pregnancy based upon measurements of anti-factor Xa levels","volume":"18","author":"Gyamfi","year":"2005","journal-title":"J Matern Fetal Neonatal Med"},{"key":"10.1016\/j.jtha.2026.08.017_bib68","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S0002-9378(03)00953-0","article-title":"Tinzaparin sodium for thrombosis treatment and prevention during pregnancy","volume":"190","author":"Smith","year":"2004","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.jtha.2026.08.017_bib69","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejogrb.2003.09.010","article-title":"Is the monitoring of anti-Xa activity necessary in pregnant women undergoing thromboprophylaxis?","volume":"114","author":"O\u2019Connell","year":"2004","journal-title":"European Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.jtha.2026.08.017_bib70","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1160\/TH03-10-0618","article-title":"Low molecular weight heparin (tinzaparin) therapy for moderate risk thromboprophylaxis during pregnancy. A pharmacokinetic study","volume":"92","author":"Norris","year":"2004","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.08.017_bib71","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.ajog.2004.05.050","article-title":"A prospective trial that demonstrates that dalteparin requirements increase in pregnancy to maintain therapeutic levels of anticoagulation","volume":"191","author":"Barbour","year":"2004","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.jtha.2026.08.017_bib72","first-page":"1307","article-title":"A longitudinal study of maternal dose response to low molecular weight heparin in pregnancy","volume":"101","author":"Sephton","year":"2003","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jtha.2026.08.017_bib73","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1046\/j.1471-0528.2003.02182.x","article-title":"Low molecular weight heparin (dalteparin) for the treatment of venous thromboembolism in pregnancy","volume":"110","author":"Jacobsen","year":"2003","journal-title":"BJOG"},{"key":"10.1016\/j.jtha.2026.08.017_bib74","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1097\/00001721-200312000-00007","article-title":"Thromboprophylaxis with unmonitored intermediate-dose low molecular weight heparin in pregnancies with a previous arterial or venous thrombotic event","volume":"14","author":"Hunt","year":"2003","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.jtha.2026.08.017_bib75","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1111\/j.1471-0528.2002.01525.x","article-title":"Low molecular weight heparin for the treatment of venous thromboembolism in pregnancy: a case series","volume":"109","author":"Rodie","year":"2002","journal-title":"BJOG"},{"key":"10.1016\/j.jtha.2026.08.017_bib76","first-page":"127","article-title":"Anti-Xa activity with low-molecular-weight heparin, enoxaparin, during pregnancy in women with mechanical heart valves","volume":"45","author":"Izaguirre","year":"2002","journal-title":"Proc West Pharmacol Soc"},{"key":"10.1016\/j.jtha.2026.08.017_bib77","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/00001721-200204000-00002","article-title":"The assay of overall haemostasis potential used to monitor the low molecular mass (weight) heparin, dalteparin, treatment in pregnant women with previous thromboembolism","volume":"13","author":"Antovic","year":"2002","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.jtha.2026.08.017_bib78","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0020-7292(00)00290-3","article-title":"Prophylaxis and treatment of thromboembolic diseases during pregnancy with dalteparin","volume":"71","author":"Rey","year":"2000","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.jtha.2026.08.017_bib79","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1111\/j.1471-0528.2000.tb11110.x","article-title":"Antenatal use of enoxaparin for prevention and treatment of thromboembolism in pregnancy","volume":"107","author":"Ellison","year":"2000","journal-title":"BJOG"},{"key":"10.1016\/j.jtha.2026.08.017_bib80","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0049-3848(99)00228-5","article-title":"Pharmacokinetic profile of a low-molecular weight heparin (reviparin) in pregnant patients. A prospective cohort study","volume":"98","author":"Crowther","year":"2000","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2026.08.017_bib81","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1159\/000040922","article-title":"Anti-activated factor X profiles in pregnant women receiving antenatal thromboprophylaxis with enoxaparin","volume":"101","author":"Brennand","year":"1999","journal-title":"Acta Haematol"},{"key":"10.1016\/j.jtha.2026.08.017_bib82","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/00001721-199806000-00006","article-title":"A pharmacokinetic study of dalteparin (Fragmin) during late pregnancy","volume":"9","author":"Blomb\u00e4ck","year":"1998","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.jtha.2026.08.017_bib83","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1055\/s-0038-1655903","article-title":"Thromboprophylaxis with low molecular weight heparin (Fragmin) in high risk pregnancies","volume":"77","author":"Hunt","year":"1997","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.08.017_bib84","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0301-2115(97)00110-3","article-title":"Thrombosis prophylaxis after treatment during pregnancy","volume":"74","author":"Daskalakis","year":"1997","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.jtha.2026.08.017_bib85","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0020-7292(94)90351-4","article-title":"Thromboembolic prophylaxis with low molecular weight heparin during pregnancy","volume":"47","author":"Rasmussen","year":"1994","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.jtha.2026.08.017_bib86","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/S0002-9378(97)70403-4","article-title":"Low-molecular-weight heparin for obstetric thromboprophylaxis: experience of sixty-nine pregnancies in sixty-one women at high risk","volume":"176","author":"Nelson-Piercy","year":"1997","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.jtha.2026.08.017_bib87","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1111\/j.1471-0528.2012.03359.x","article-title":"Low-molecular-weight heparin or warfarin for anticoagulation in pregnant women with mechanical heart valves: what are the risks? A retrospective observational study","volume":"119","author":"Basude","year":"2012","journal-title":"BJOG"},{"key":"10.1016\/j.jtha.2026.08.017_bib88","first-page":"591","article-title":"Pregnancy outcomes compared in women with mechanical heart valve replacements anticoagulated with warfarin and enoxaparin in pregnancy","volume":"67","author":"Vijayan","year":"2012","journal-title":"Med J Malaysia"},{"key":"10.1016\/j.jtha.2026.08.017_bib89","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.ajog.2004.05.064","article-title":"Pregnancy outcome in women with prosthetic heart valves","volume":"191","author":"Nassar","year":"2004","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.jtha.2026.08.017_bib90","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1001\/archinte.163.22.2788-a","article-title":"Anticoagulation of pregnant women with mechanical heart valves using low-molecular-weight heparin","volume":"163","author":"Bauersachs","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jtha.2026.08.017_bib91","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1055\/s-0037-1615718","article-title":"The impact of dalteparin (Fragmin) on thrombin generation in pregnant women with venous thromboembolism: significance of the factor V Leiden mutation","volume":"85","author":"Schambeck","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.08.017_bib92","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1055\/s-0039-1678667","article-title":"Comparison of continuation of low-molecular-weight heparin versus switching to unfractionated heparin in the peripartum","volume":"37","author":"Enakpene","year":"2020","journal-title":"Am J Perinatol"},{"key":"10.1016\/j.jtha.2026.08.017_bib93","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/clpt.2008.73","article-title":"Changes in enoxaparin pharmacokinetics during pregnancy and implications for antithrombotic therapeutic strategy","volume":"84","author":"Lebaudy","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jtha.2026.08.017_bib94","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1592\/phco.31.7.678","article-title":"Dosing and monitoring of low-molecular-weight heparin in high-risk pregnancy: single-center experience","volume":"31","author":"Shapiro","year":"2011","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jtha.2026.08.017_bib95","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1046\/j.0004-8666.2003.00034.x","article-title":"Prophylactic and therapeutic enoxaparin during pregnancy: indications, outcomes and monitoring","volume":"43","author":"Rowan","year":"2003","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"10.1016\/j.jtha.2026.08.017_bib96","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1055\/s-0038-1646338","article-title":"Use of low molecular weight heparin in pregnancy","volume":"68","author":"Melissari","year":"1992","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.08.017_bib97","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1159\/000467385","article-title":"Thrombogenesis in thrombophilic pregnancy: evaluation of low-molecular-weight heparin prophylaxis","volume":"137","author":"Simeone","year":"2017","journal-title":"Acta Haematol"},{"key":"10.1016\/j.jtha.2026.08.017_bib98","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3109\/00016340903370098","article-title":"Venous thromboembolism in pregnancy: prophylaxis and treatment with low molecular weight heparin","volume":"89","author":"Andersen","year":"2010","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.jtha.2026.08.017_bib99","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1160\/TH14-05-0452","article-title":"Thrombin generation and low-molecular-weight heparin prophylaxis in pregnant women with thrombophilia","volume":"113","author":"Selmeczi","year":"2015","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.08.017_bib100","doi-asserted-by":"crossref","DOI":"10.1177\/10760296211016550","article-title":"Prophylactic anticoagulation with intermediate-dose certoparin in vascular-risk pregnancies-the PACER-VARP Registry","volume":"27","author":"Gr\u00fcnewald","year":"2021","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.jtha.2026.08.017_bib101","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/j.1471-0528.1998.tb10212.x","article-title":"Puerperal thromboprophylaxis: comparison of the anti-Xa activity of enoxaparin and unfractionated heparin","volume":"105","author":"Gibson","year":"1998","journal-title":"Br J Obstet Gynaecol"},{"key":"10.1016\/j.jtha.2026.08.017_bib102","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1136\/jim-2021-002050","article-title":"Comparison of doses of heparin for venous thromboembolism and bleeding in pregnant women","volume":"70","author":"Xiao","year":"2022","journal-title":"J Investig Med"},{"key":"10.1016\/j.jtha.2026.08.017_bib103","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/j.1538-7836.2011.04186.x","article-title":"Prophylaxis with low-dose low-molecular-weight heparin during pregnancy and postpartum: is it effective?","volume":"9","author":"Roeters van Lennep","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.08.017_bib104","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.thromres.2018.08.007","article-title":"The effect on thrombin generation and anti-Xa levels of thromboprophylaxis dose adjustment in post-cesarean obese patients - a prospective cohort study","volume":"170","author":"Rottenstreich","year":"2018","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2026.08.017_bib105","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.thromres.2014.04.006","article-title":"Weight-adjusted LMWH prophylaxis provides more effective thrombin inhibition in morbidly obese pregnant women","volume":"134","author":"Ismail","year":"2014","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2026.08.017_bib106","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1097\/AOG.0000000000000873","article-title":"Enoxaparin dosing after cesarean delivery in morbidly obese women","volume":"125","author":"Overcash","year":"2015","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jtha.2026.08.017_bib107","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/imj.13117","article-title":"Evaluation of therapeutic enoxaparin in a pregnant population at a tertiary hospital","volume":"46","author":"Petrie","year":"2016","journal-title":"Intern Med J"},{"key":"10.1016\/j.jtha.2026.08.017_bib108","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.amjcard.2020.04.010","article-title":"Comparison of different anticoagulation regimens regarding maternal and fetal outcomes in pregnant patients with mechanical prosthetic heart valves (from the multicenter ANATOLIA-PREG Registry)","volume":"127","author":"G\u00fcner","year":"2020","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jtha.2026.08.017_bib109","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12185-020-02873-2","article-title":"A prospective cohort study comparing achieved anti-factor Xa peak levels in pregnant and non-pregnant patients receiving therapeutic-dose low-molecular-weight heparin","volume":"112","author":"Aleidan","year":"2020","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jtha.2026.08.017_bib110","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0049-3848(02)00074-9","article-title":"Treatment of deep venous thrombosis with low-molecular-weight heparin during pregnancy","volume":"106","author":"Ulander","year":"2002","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2026.08.017_bib111","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s12325-008-0068-0","article-title":"Comparison of different dose regimens of enoxaparin in deep vein thrombosis therapy in pregnancy","volume":"25","author":"Narin","year":"2008","journal-title":"Adv Ther"},{"key":"10.1016\/j.jtha.2026.08.017_bib112","first-page":"56","article-title":"Clinical study on pregnant women with thrombophilia, regarding the monitorization of the treatment with tinzaparin sodium using the anti-FXa activity","volume":"LIV","author":"Bischofberger","year":"2006","journal-title":"Farmacia"},{"key":"10.1016\/j.jtha.2026.08.017_bib113","doi-asserted-by":"crossref","DOI":"10.1177\/10760296231160748","article-title":"A Longitudinal study of thrombosis and bleeding outcomes with thromboprophylaxis in pregnant women at intermediate and high risk of VTE","volume":"29","author":"Schapkaitz","year":"2023","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.jtha.2026.08.017_bib114","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.thromres.2012.03.007","article-title":"The risk of postpartum hemorrhage in women using high dose of low-molecular-weight heparins during pregnancy","volume":"130","author":"Knol","year":"2012","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2026.08.017_bib115","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1177\/00033197221126244","article-title":"Prophylactic dose of dalteparin in pregnant women with history of venous thromboembolisms and\/or thrombophilia: real-world data","volume":"74","author":"Novak","year":"2023","journal-title":"Angiology"},{"key":"10.1016\/j.jtha.2026.08.017_bib116","doi-asserted-by":"crossref","first-page":"62","DOI":"10.52142\/omujecm.39.1.13","article-title":"A comparison of the safety of two different enoxaparin doses for thromboprophylaxis following cesarean section","volume":"39","author":"Sahin","year":"2022","journal-title":"J Exp Clin Med"},{"key":"10.1016\/j.jtha.2026.08.017_bib117","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ahj.2024.03.015","article-title":"Combination anticoagulation strategy in pregnancy with mechanical valves: the KYBELE study","volume":"273","author":"\u00d6zkan","year":"2024","journal-title":"Am Heart J"},{"key":"10.1016\/j.jtha.2026.08.017_bib118","article-title":"The safety and efficacy of low-molecular-weight heparin in pregnant women with rheumatic heart disease and valves replacement","volume":"14","author":"Alghamdi","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.jtha.2026.08.017_bib119","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s13224-015-0678-9","article-title":"Pregnancy outcome in women with mechanical prosthetic heart valves treated with unfractionated heparin (UFH) or enoxaparin","volume":"66","author":"Khader","year":"2016","journal-title":"J Obstet Gynaecol India"},{"key":"10.1016\/j.jtha.2026.08.017_bib120","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2011-000257","article-title":"Incidence of postpartum haemorrhage in women receiving therapeutic doses of low-molecular-weight heparin: results of a retrospective cohort study","volume":"1","author":"Roshani","year":"2011","journal-title":"BMJ Open"},{"key":"10.1016\/j.jtha.2026.08.017_bib121","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1160\/TH16-03-0221","article-title":"Adjusting enoxaparin dosage according to anti-FXa levels and pregnancy outcome in thrombophilic women. A randomised controlled trial","volume":"116","author":"Salim","year":"2016","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.08.017_bib122","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1055\/s-0037-1616738","article-title":"Thromboprophylaxis following caesarean section--a comparison of the antithrombotic properties of three low molecular weight heparins--dalteparin, enoxaparin and tinzaparin","volume":"86","author":"Ellison","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.08.017_bib123","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jsgi.2004.02.007","article-title":"Pharmacokinetics of low molecular weight heparin and unfractionated heparin in pregnancy","volume":"11","author":"Ensom","year":"2004","journal-title":"J Soc Gynecol Investig"},{"key":"10.1016\/j.jtha.2026.08.017_bib124","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0049-3848(99)00110-3","article-title":"Thromboprophylaxis with low molecular weight heparin (dalteparin) in pregnancy","volume":"96","author":"Pettil\u00e4","year":"1999","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2026.08.017_bib125","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/S0140-6736(14)60793-5","article-title":"Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial","volume":"384","author":"Rodger","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2026.08.017_bib126","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1016\/S0140-6736(22)02128-6","article-title":"Intermediate-dose versus low-dose low-molecular-weight heparin in pregnant and post-partum women with a history of venous thromboembolism (Highlow study): an open-label, multicentre, randomised, controlled trial","volume":"400","author":"Bistervels","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2026.08.017_bib127","article-title":"Comparison of postpartum anti-Xa levels following enoxaparin administration to prevent venous thromboembolism using 2 weight-based protocols: a randomized controlled trial","volume":"5","author":"Haj","year":"2023","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.jtha.2026.08.017_bib128","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/AOG.0000000000004937","article-title":"Weight-based compared with fixed-dose enoxaparin prophylaxis after cesarean delivery: a randomized controlled trial","volume":"140","author":"Bruno","year":"2022","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jtha.2026.08.017_bib129","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1160\/TH14-06-0485","article-title":"Low-molecular-weight heparin to prevent postpartum venous thromboembolism. A pilot randomised placebo-controlled trial","volume":"113","author":"Rodger","year":"2015","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.08.017_bib130","first-page":"211","article-title":"The rheological changes after cesarean section: the influence of low molecular weight or unfractionated heparin on the rheological properties of blood","volume":"37","author":"Heilmann","year":"2007","journal-title":"Clin Hemorheol Microcirc"},{"key":"10.1016\/j.jtha.2026.08.017_bib131","doi-asserted-by":"crossref","first-page":"209","DOI":"10.34172\/jcvtr.2020.35","article-title":"Pregnancy outcome in women with mechanical prosthetic heart valvesat their first trimester of pregnancy treated with unfractionated heparin (UFH) or enoxaparin: a randomized clinical trial","volume":"12","author":"Movahedi","year":"2020","journal-title":"J Cardiovasc Thorac Res"},{"key":"10.1016\/j.jtha.2026.08.017_bib132","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1055\/s-0041-1726374","article-title":"Anti-Xa monitoring of low-molecular-weight heparin during pregnancy: a systematic review","volume":"47","author":"Kjaergaard","year":"2021","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jtha.2026.08.017_bib133","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.1093\/eurheartj\/ehaf193","volume":"46","author":"De Backer","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jtha.2026.08.017_bib134","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S1701-2163(15)30569-7","article-title":"SOGC clinical practice guideline venous thromboembolism and antithrombotic therapy in pregnancy VTE in pregnancy guideline working group","volume":"36","author":"Chan","year":"2014","journal-title":"J Obstet Gynaecol Can"},{"key":"10.1016\/j.jtha.2026.08.017_bib135","first-page":"e72","article-title":"2020 ACC\/AHA guideline for the management of patients with valvular heart disease: a report of the American college of cardiology\/American heart association joint committee on clinical practice guidelines","volume":"143","author":"Otto","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2026.08.017_bib136","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/bjh.18781","article-title":"British society for haematology guideline for anticoagulant management of pregnant individuals with mechanical heart valves","volume":"202","author":"Lester","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2026.08.017_bib137","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1055\/a-2325-5658","article-title":"Anticoagulant therapy in pregnant women with mechanical heart valves: Italian federation of centers for diagnosis and surveillance of the antithrombotic therapies (FCSA) position paper","volume":"124","author":"Campello","year":"2024","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.08.017_bib138","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1161\/CIRCULATIONAHA.115.015242","article-title":"Pregnancy in women with a mechanical heart valve: data of the European society of cardiology registry of pregnancy and cardiac disease (ROPAC)","volume":"132","author":"van Hagen","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2026.08.017_bib139","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ahj.2024.09.008","article-title":"Outcome reporting in cardio-obstetrics studies: a systematic review","volume":"278","author":"Hall","year":"2024","journal-title":"Am Heart J"},{"key":"10.1016\/j.jtha.2026.08.017_bib140","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.124.011754","article-title":"Core outcome set for studies on cardiac disease in pregnancy (COSCarP): an international Delphi consensus study","volume":"18","author":"Ashraf","year":"2025","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jtha.2026.08.017_bib141","article-title":"Multifunctional applications and research advances of low-molecular-weight heparin","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jtha.2026.08.017_bib142","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.pmrj.2011.10.007","article-title":"Enoxaparin versus tinzaparin for venous thromboembolic prophylaxis during rehabilitation after acute spinal cord injury: a retrospective cohort study comparing safety and efficacy","volume":"4","author":"Marciniak","year":"2012","journal-title":"PM R"},{"key":"10.1016\/j.jtha.2026.08.017_bib143","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1093\/ehjcvp\/pvae064","article-title":"Update on antithrombotic therapy and body mass: a clinical consensus statement of the European society of cardiology working group on cardiovascular pharmacotherapy and the european society of cardiology working group on thrombosis","volume":"10","author":"Gigante","year":"2024","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.jtha.2026.08.017_bib144","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3390\/ph19020215","article-title":"Therapeutic drug monitoring of direct oral anticoagulants and its association with clinical outcomes: a systematic review and meta-analysis","volume":"19","author":"Bakir","year":"2026","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.jtha.2026.08.017_bib145","doi-asserted-by":"crossref","first-page":"7793","DOI":"10.1038\/s41598-024-58200-w","article-title":"Assessment of the practical impact of adjusting beta-lactam dosages based on therapeutic drug monitoring in critically ill adult patients: a systematic review and meta-analysis of randomized clinical trials and observational studies","volume":"14","author":"Guly\u00e1s","year":"2024","journal-title":"Sci Rep"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783626005416?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783626005416?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T08:26:31Z","timestamp":1793348791000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783626005416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":142,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S1538783626005416"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2026.08.017","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of antifactor Xa monitoring in the dosing and administration of low-molecular-weight heparins in pregnancy: a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2026.08.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}